This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Zotepine, Nipolept, Losizopilon, Lodopin, Majorpin, Setous, Zopite
Description: Zoleptil is an atypical antipsychotic drug with a higher affinity for the serotonin 5-HT2 receptor relative to its affinity for the dopamine D-2 receptor. Though the exact mechanism is unclear (either due to a difference in affinities for such receptors or fast dissociation from the D-2 receptor), atypical antipsychotics are able to produce an antipsychotic effect (through blockade of D-2 receptors in the ventral striatum) with fewer extrapyramidal motor function side effects (or EPSs, which are caused by blockade of D-2 receptors in the dorsal striatum).
Zotepine affects the dopamine D1 and D2, serotonin 5HT2a, 5HT2c, 5HT6, and 5HT7 receptors. In addition, it inhibits the reuptake of noradrenaline.
Partners: BASF AG Orion Corporation
Additional information available to subscribers only: